Levobupivakain Kabi

Levobupivacaine, the active ingredient in Levobupivakain Kabi, is a local anesthetic presented as a sterile solution for epidural, infiltration, intrathecal and peripheral nerve block use. It provides regional anesthesia and analgesia for surgical procedures, postoperative pain control and labor.

GNH USA supplies Levobupivakain Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levobupivakain Kabi, a local anesthetic, is employed to achieve analgesia by blocking nerve conduction in various clinical settings. - Surgical anesthesia: provides intra‑operative anesthesia for a wide range of surgeries. - Postoperative analgesia: offers extended pain relief after surgical procedures. - Labor analgesia: enables effective pain control during childbirth.

Levobupivakain Kabi may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure after administration. - Bradycardia: slowed heart rate observed in some patients. - Dizziness: sensation of light‑headedness during or after the block. - Nausea: mild gastrointestinal upset. - Metallic taste: transient taste alteration. - Headache: mild to moderate headache post‑procedure.

Serious or Rare Side Effects: - Seizures: central nervous system excitation leading to convulsions. - Cardiac arrest: severe cardiac depression or arrhythmia. - Respiratory depression: reduced breathing effort. - Allergic reactions: rash, urticaria or anaphylaxis. - Prolonged motor block: extended loss of muscle function. - Methemoglobinemia: rare blood disorder causing reduced oxygen delivery.

When using Levobupivakain Kabi, several precautions should be observed to minimize risks. - Patient assessment: evaluate cardiovascular and neurological status before administration. - Dose limitation: avoid exceeding recommended maximum doses for the specific route. - Concurrent CNS depressants: use with caution when combined with other central nervous system depressants. - Pregnancy: avoid unless the potential benefit justifies the potential risk to the fetus. - Elderly patients: monitor closely for prolonged sensory or motor block. - Store at controlled room temperature: keep in the original container, protect from light and moisture.

Levobupivakain Kabi can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may increase cardiotoxicity. - Other local anesthetics: additive neuro‑ and cardiotoxic effects. - Beta‑blockers: heightened risk of severe bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - Opioids: enhanced sedation and respiratory depression. - Sedatives or hypnotics: increased central nervous system depression.